Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
Li Tzong Chen, Jens T. Siveke, Andrea Wang-Gillam, Chung Pin Li, György Bodoky, Andrew P. Dean, Yan Shen Shan, Gayle S. Jameson, Teresa Macarulla, Kyung Hun Lee, David Cunningham, Jean Frédéric Blanc, Chang Fang Chiu, Gilberto Schwartsmann, Fadi S. Braiteh, Khalid Mamlouk, Bruce Belanger, Floris A. de Jong, Richard A. Hubner
Fingerprint
Dive into the research topics of 'Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial'. Together they form a unique fingerprint.